NEONasdaqServices-Testing LaboratoriesUS GAAP · USD

NeoGenomics, Inc

NeoGenomics is a U.S.-based cancer diagnostics company that provides oncology testing and consultative pathology services to help clinicians identify, classify, and monitor cancer. It operates a network of cancer-focused laboratories in the United States and the United Kingdom and also serves pharmaceutical customers with clinical trial testing, biomarker analysis, and oncology data solutions.

Kysy yhtiöstä
Liikevaihto727milj. USD
+10,1 %v/v
Liikevoitto (EBIT)−116milj. USD
−25,8 %v/v
EBIT-marginaali−15,9%
−2,0 %-yks.v/v
Nettotulos−108milj. USD
−37,2 %v/v
Vapaa kassavirta−21,8milj. USD
+36,0 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−2000200400600800milj. USD2020: 444 milj. USD2020: EBIT −14 milj. USD20202021: 484 milj. USD2021: EBIT −119 milj. USD20212022: 510 milj. USD2022: EBIT −158 milj. USD20222023: 592 milj. USD2023: EBIT −108 milj. USD20232024: 661 milj. USD2024: EBIT −92 milj. USD20242025: 727 milj. USD2025: EBIT −116 milj. USD2025727−116
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Clinical oncology testing55 %

Diagnostic laboratory testing used by physicians to detect, classify, and monitor cancer.

Molecular and NGS testing20 %

Next-generation sequencing and molecular assays used for therapy selection and disease characterization.

MRD testing10 %

Minimal residual disease testing used to detect very low levels of cancer after treatment.

Professional interpretation and consultative services7 %

Physician and molecular expert review of laboratory results, including second-opinion pathology.

Pharmaceutical development services5 %

Laboratory testing, biomarker analysis, and study support for sponsor-led clinical research.

Oncology data solutions3 %

Licensing of de-identified oncology data to pharma and biotech customers for research and targeting.

Tuotteet

Raportoitu · osuus liikevaihdosta
71,3%16,2%12,5%FY2025100 %
  • Client Direct Billing71,3 %
  • Commercial Insurance16,2 %
  • Medicare and Other Governmental12,5 %

Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

NeoGenomics sells primarily to healthcare providers that need specialized cancer testing and expert interpretation, including community oncology practices, hospitals, pathology labs, reference labs, and academic centers. It also serves pharmaceutical and biotech sponsors that need biomarker testing, sample analysis, and data support for oncology drug development and clinical trials. The company’s value proposition is speed, breadth of oncology test menu, and consultative support for complex cases.

Community oncology practices

Buy routine and advanced cancer tests, MRD assays, and consultative support to manage patients locally.

Hospitals and hospital pathology labs

Use NeoGenomics for specialized reference testing, complex case review, and overflow capacity.

Pathology and reference laboratories

Send difficult specimens for advanced molecular testing and expert interpretation.

Academic medical centers

Buy specialized oncology diagnostics for complex cases, research, and precision medicine programs.

Pharmaceutical and biotech sponsors

Purchase lab services, biomarker analysis, and oncology data for clinical trials and drug development.

Strategia

NeoGenomics is focused on expanding share in oncology diagnostics through new tests, especially therapy selection and MRD, while improving the customer experience and operational efficiency. The company is also pushing deeper into community oncology and using partnerships, sales coverage, and data-driven services to broaden its reach. Its strategy combines product innovation with service differentiation to defend pricing and win more complex cases.

Launch next-generation precision diagnostic testsLyhyt aikaväli

New therapy-selection and MRD assays support higher-value testing and strengthen the oncology menu.

Expand community oncology presenceKeskipitkä aikaväli

Community oncology is a key growth channel where broad menus and service quality can win share.

Optimize customer experience and operationsLyhyt aikaväli

Automation and platform upgrades can improve turnaround times, margins, and retention.

Grow pharma development and data solutionsKeskipitkä aikaväli

Sponsor services and data licensing diversify revenue beyond routine clinical testing.

Maantiede

NeoGenomics operates mainly in the United States, where most testing, sales, and customer relationships are concentrated. It also has a laboratory presence in Cambridge, United Kingdom, and receives some samples and data from outside the U.S., creating limited but real international compliance exposure. Geography matters because the business depends on specimen logistics, local lab capacity, and healthcare privacy rules across jurisdictions.

Riskit

NeoGenomics faces execution risk from rapid scientific change, capacity constraints, and the need to keep launching relevant tests in a competitive market. Its business is also exposed to reimbursement pressure, regulatory scrutiny in healthcare referrals and privacy, and operational disruption from cyberattacks or lab system failures. Goodwill and intangible asset impairment is another meaningful risk because acquisitions have created large balance-sheet estimates tied to future performance.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Competition and price pressure1Technology obsolescence2Goodwill and intangible asset impairment3Capacity constraints4Cybersecurity and IT disruption5Regulatory and privacy compliance6
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Competition and price pressureVaikutus: KorkeaTodennäköisyys: Korkea

    The company competes with large reference labs and CROs, which can pressure pricing and win rates.

    Kohdistuu: Clinical oncology testing and pharma services

  2. Technology obsolescenceVaikutus: KorkeaTodennäköisyys: Korkea

    The company must continually develop or license new testing technologies to stay relevant.

    KohdistuuMolecular testingNGSMRD
  3. Goodwill and intangible asset impairmentVaikutus: KorkeaTodennäköisyys: Korkea

    Acquisition-related assets depend on future cash flows and can be written down if assumptions weaken.

    Kohdistuu: Acquired businesses and intangibles

  4. Capacity constraintsVaikutus: KorkeaTodennäköisyys: Kohtalainen

    If lab throughput or staffing cannot keep pace with demand, growth and service levels can suffer.

    Kohdistuu: Laboratory operations and turnaround times

  5. Cybersecurity and IT disruptionVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Lab operations depend on LIMS, CRM, and data systems; outages can halt testing and billing.

    KohdistuuSpecimen processingResults deliveryBilling
  6. Regulatory and privacy complianceVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Healthcare referral laws, HIPAA, and GDPR can create penalties and operational restrictions.

    Kohdistuu: U.S. and U.K./EU data and clinical workflows

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition and accounts receivable

Clinical lab revenue depends on payer adjudication, contract terms, and collection timing.

Vaikutus: Can affect reported revenue, bad debt, and cash conversion

Goodwill and intangible impairment

Acquisition-related assets are tested against future cash flow assumptions and market conditions.

Vaikutus: Can create large non-cash charges to earnings

Stock-based compensation

A meaningful portion of operating expense is equity-based and affects comparability.

Vaikutus: Reduces reported profit without immediate cash outflow

Acquisition and integration costs

Recent acquisitions add one-time expenses that can obscure underlying operating trends.

Vaikutus: Affects adjusted EBITDA and GAAP margin comparisons

Amortization of acquired intangibles

Purchased technology and customer relationships are amortized over time.

Vaikutus: Reduces operating income and net income

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Nuvectis Pharma, Inc.

NVCT · Pharmaceutical Preparations

Myriad Genetics, Inc

MYGN · In Vitro & In Vivo Diagnostic Substances

Neogen Corporation

NEOG · In Vitro & In Vivo Diagnostic Substances

NeOnc Technologies Holdings, Inc

NTHI · Pharmaceutical Preparations

Fulgent Genetics, Inc.

FLGT · Services-Medical Laboratories

Biodesix, Inc

BDSX · Services-Medical Laboratories

Päivitetty: 24.9.2026